Preclinical and clinical evaluation of Siddha classical drug KARUNJEERAKA MATHIRAI (oral administration)along with application of NUNAA TAILAM(external) in the management of VITILIGO in children

Preclinical and clinical evaluation of the effect on oral administration of KARUNJEERAKA MATHIRAI along with external application of NUNAA TAILAM in the management of VENPADAI in children

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/01/039863

Enrollment

Registered

2022-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: KARUNJEERAKA MATHIRAI: 1-2 tablet(According to the age of the patient) with water x 45 days Intervention2: NUNAA TAILAM: external application x 45 days Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.Hypo pigemented patches surrounded by hyper pigemneted border present in any part of the body

Exclusion criteria

Exclusion criteria: 1.Children above 12 years 2.Children below 3 years 3.Albinism 4.Pie-baldism 5.Hypo pigmented patches start firstly in lips and genital area 6.Depigemented patches after burns 7.Juvenile diabetes with vitiligo

Design outcomes

Primary

Measure	Time frame
Reduction in clinical symptoms 45 daysTimepoint: Reduction in clinical symptoms 45 days	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr K Shyamala MD s

Government Siddha Medical College and Hospital, Palayamkottai.

shyamsujisathya@gmail.com9442277124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026